Marksans Pharma receives UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
Marksans Pharma announced that UK MHRA has granted Market
Authorisation to the Company's wholly owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.
Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Buzzing :
Greece in crisisTravel & Budget & EuropeSaaS $ Email MarketingHarnautBlacklisting Policy 2Question Paper Leak 2A big moment for small armsAI in Financial Markets: How Technology is Changing Investing'India's size and diversity make it a powerful innovation engine'Datanomics: Housing, gold loans drive household debt to a decade highSamrat ChoudharyEl Nino
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jan 23 2023 | 1:41 PM IST